Back to Authors

Kaufmann, Scott H.

https://orcid.org/0000-0002-4900-7145

A5054370710 | I1330342723

Mayo Clinic

Mayo Clinic

Citations 321

Faculty Opinions recommendation of Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 17, 2016 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.726465378.793525471

Faculty Opinions recommendation of Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 17, 2016 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.726356653.793525469

Faculty Opinions recommendation of The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 17, 2016 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.726281749.793525470

Faculty Opinions recommendation of Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 17, 2016 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.726978664.793525467

Faculty Opinions recommendation of A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 17, 2016 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.726978662.793525466

Faculty Opinions recommendation of Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 17, 2016 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.725994198.793525468

Faculty Opinions recommendation of A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 17, 2016 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.725400916.793525465

Faculty Opinions recommendation of Physiological restraint of Bak by Bcl-xL is essential for cell survival.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 17, 2016 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.726369624.793525464

Faculty Opinions recommendation of An interconnected hierarchical model of cell death regulation by the BCL-2 family.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 17, 2016 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.725773056.793525463

Faculty Opinions recommendation of Bax assembly into rings and arcs in apoptotic mitochondria is linked to membrane pores.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 17, 2016 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.726084558.793525460